PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjLink to Publisher's site
 
BMJ. 1994 January 22; 308(6923): 235–246.
PMCID: PMC2539330

Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration.

Abstract

OBJECTIVE--To determine the efficacy of antiplatelet therapy as prophylaxis against deep venous thrombosis or pulmonary embolism in surgical and high risk medical patients. DESIGN--Overviews of all randomised trials of antiplatelet therapy that could have been available by March 1990 and in which deep venous thrombosis was assessed systematically. SETTING--53 trials (total 8400 patients) of an average of two weeks of antiplatelet therapy versus control in general or orthopaedic surgery; nine trials (600 patients) of antiplatelet therapy versus control in other types of immobility; 18 trials (1000 patients) of one antiplatelet regimen versus another. RESULTS--Overall, a few weeks of antiplatelet therapy produced a highly significant (2P < 0.00001) reduction in deep venous thrombosis. 25% of patients allocated antiplatelet therapy versus 34% of appropriately adjusted controls had deep venous thrombosis detected by systematic fibrinogen scanning or venography, representing prevention in about 90 patients per 1000 allocated antiplatelet therapy. There was an even greater proportional reduction in pulmonary embolism: such emboli were detected among 47 (1.0%) antiplatelet allocated patients versus an adjusted control total of 129 (2.7%), representing prevention among about 17 patients per 1000 treated (2P < 0.00001). In analyses confined to surgical trials, the proportional reductions were similar and separately significant for nonfatal pulmonary embolism (0.7% antiplatelet therapy v 1.8% control; 2P < 0.00001) and for deaths attributed to pulmonary embolism (0.2% v 0.9%; 2P = 0.0001). There was a slight but non-significant excess of deaths from other causes (1.0% v 0.7%), which made the difference in total mortality nonsignificant, though still favourable (1.2% v 1.5%). Information on adding antiplatelet therapy to heparin was limited but, at least for pulmonary embolism, suggested more protection from the combination than from heparin alone. The proportional reduction in the odds of suffering a deep venous thrombosis was roughly the same in patients having general surgery, traumatic orthopaedic surgery, and elective orthopaedic surgery (and in medical patients who were at increased risk of thromboembolism). For pulmonary embolism the numbers affected were smaller, but again the reductions were highly significant both in general surgery (16 (0.5%) v 58 (1.7%) pulmonary emboli; 2P < 0.0001) and in orthopaedic surgery (28 (2.7%) v 63 (6.1%) pulmonary emboli; 2P < 0.0002). CONCLUSION--It had previously been supposed that antiplatelet therapy did not influence venous thromboembolism, and many surgeons and physicians do not use it routinely for thromboprophylaxis, even for patients who are at substantial risk of deep venous thrombosis or pulmonary embolism. These results indicate that antiplatelet therapy--either alone or, for greater effect, in addition to other proved forms of thromboprophylaxis (such as subcutaneous heparin)--should be considered.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Kakkar VV. Prevention of venous thromboembolism. Clin Haematol. 1981 Jun;10(2):543–582. [PubMed]
  • Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. [PubMed]
  • Clagett GP, Anderson FA, Jr, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism. Chest. 1992 Oct;102(4 Suppl):391S–407S. [PubMed]
  • Goldhaber SZ, Morpurgo M. Diagnosis, treatment, and prevention of pulmonary embolism. Report of the WHO/International Society and Federation of Cardiology Task Force. JAMA. 1992 Oct 7;268(13):1727–1733. [PubMed]
  • Gent M, Roberts RS. A meta-analysis of the studies of dihydroergotamine plus heparin in the prophylaxis of deep vein thrombosis. Chest. 1986 May;89(5 Suppl):396S–400S. [PubMed]
  • Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988 May 5;318(18):1162–1173. [PubMed]
  • Grandi A, Parodi JC, Rotondaro D, Soffer F, Alle E. Prevención de la flebotrombosis post-operatoria. Medicina (B Aires) 1979 May-Jun;39(3):379–383. [PubMed]
  • Loew D, Wellmer HK, Baer U, Merguet H, Rumpf P, Petersen H, Bromig G, Persch WF, Marx FJ, von Bary SM. Postoperative Thrombembolie-Prophylaxe mit Acetylsalicylsäure. Dtsch Med Wochenschr. 1974 Mar 22;99(12):565–572. [PubMed]
  • Clagett GP, Schneider P, Rosoff CB, Salzman EW. The influence of aspirin on postoperative platelet kinetics and venous thrombosis. Surgery. 1975 Jan;77(1):61–74. [PubMed]
  • Renney JT, O'Sullivan EF, Burke PF. Prevention of postoperative deep vein thrombosis with dipyridamole and aspirin. Br Med J. 1976 Apr 24;1(6016):992–994. [PMC free article] [PubMed]
  • Plante J, Boneu B, Vaysse C, Barret A, Gouzi M, Bierme R. Dipyridamole-aspirin versus low doses of heparin in the prophylaxis of deep venous thrombosis in abdominal surgery. Thromb Res. 1979 Feb-Mar;14(2-3):399–403. [PubMed]
  • Schreiber U, Hartung B. Postoperative Thromboembolieprophylaxe bei Patienten mit allgemeinchirurgischen Operationen. Zentralbl Chir. 1979;104(18):1214–1220. [PubMed]
  • Hartung B, Schreiber U, Rödiger H. Testung des Thrombozytenaggregationshemmers MICRISTIN auf seine Wirksamkeit als Thromboembolieprophylaktikum in der postoperativen Phase nach chirurgischen Eingriffen. Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):810–827. [PubMed]
  • Zekert F, Hofbauer F, Mühlbacher F. Thromboembolie-Prophylaxe in der Abdominalchirurgie. Vergleich von niedrig dosiertem Heparin, Azetylsalizylsäure und deren Kombination. MMW Munch Med Wochenschr. 1980 Oct 24;122(43):1495–1498. [PubMed]
  • Vinazzer H, Loew D, Simma W, Brücke P. Prophylaxis of postoperative thromboembolism by low dose heparin and by acetylsalicylic acid given simultaneously. A double blind study. Thromb Res. 1980 Jan 1;17(1-2):177–184. [PubMed]
  • Loew D, Brücke P, Simma W, Vinazzer H, Dienstl E, Boehme K. Acetylsalicylic acid, low dose heparin, and a combination of both substances in the prevention of postoperative thromboembolism. A double blind study. Thromb Res. 1977 Jul;11(1):81–86. [PubMed]
  • Zekert F, Schemper M, Neumann K. Acetylsalicylic acid in combination with dihydroergotamine for preventing thromboembolism. Haemostasis. 1982;11(3):149–153. [PubMed]
  • Turpie AG, Gent M, Doyle DJ, Saerens E, de Boer AC, Talbot C, McNamee J, Hirsh J. An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. Thromb Res. 1985 Jul 15;39(2):173–181. [PubMed]
  • Veth G, Meuwissen OJ, van Houwelingen HC, Sixma JJ. Prevention of postoperative deep vein thrombosis by a combination of subcutaneous heparin with subcutaneous dihydroergotamine or oral sulphinpyrazone. Thromb Haemost. 1985 Oct 30;54(3):570–573. [PubMed]
  • Carter AE, Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J. 1974 Jul 13;3(5923):94–95. [PMC free article] [PubMed]
  • Wood EH, Prentice CR, McGrouther DA, Sinclair J, McNicol GP. Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis. Thromb Diath Haemorrh. 1973 Sep 15;30(1):18–24. [PubMed]
  • Zekert F, Kohn P, Vormittag E, Poigenfürst J, Thien M. Thromboembolieprophylaxe mit Acetylsalicylsäure bei Operationen wegen jüfgelenksnaher Frakturen. Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed. 1974 Mar;77(3):97–110. [PubMed]
  • Morris GK, Mitchell JR. Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. Br Med J. 1977 Feb 26;1(6060):535–537. [PMC free article] [PubMed]
  • Hansen EH, Jessing P, Lindewald H, Ostergaard P, Olesen T, Malver EI. Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine. J Bone Joint Surg Am. 1976 Dec;58(8):1089–1093. [PubMed]
  • Dechavanne M, Ville D, Viala JJ, Kher A, Faivre J, Pousset MB, Dejour H. Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. Haemostasis. 1975;4(2):94–100. [PubMed]
  • Chrisman OD, Snook GA, Wilson TC, Short JY. Prevention of venous thromboembolism by administration of hydroxychloroquine. A preliminary report. J Bone Joint Surg Am. 1976 Oct;58(7):918–920. [PubMed]
  • Flicoteaux H, Kher A, Jean N, Blery M, Judet T, Honnart F, Pasteyer J. Comparision of low dose heparin and low dose heparin combined with aspirin in prevention of deep vein thrombosis after total hip replacement. Pathol Biol (Paris) 1977 Dec;25 (Suppl):55–58. [PubMed]
  • Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, DeSanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977 Dec 8;297(23):1246–1249. [PubMed]
  • McKenna R, Galante J, Bachmann F, Wallace DL, Kaushal PS, Meredith P. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J. 1980 Feb 23;280(6213):514–517. [PMC free article] [PubMed]
  • Sautter RD, Koch EL, Myers WO, Ray JR, 3rd, Mazza JJ, Larson DE, Chen HM, Milbauer JP, Treuhaft PS, Plotka ED, et al. Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement. JAMA. 1983 Nov 18;250(19):2649–2654. [PubMed]
  • Cooke ED, Dawson MH, Ibbotson RM, Bowcock SA, Ainsworth ME, Pilcher MF. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg Am. 1977 Jun;59(4):496–500. [PubMed]
  • Alfaro MJ, Páramo JA, Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemost. 1986 Aug 20;56(1):53–56. [PubMed]
  • Hume M, Bierbaum B, Kuriakose TX, Surprenant J. Prevention of postoperative thrombosis by aspirin. Am J Surg. 1977 Apr;133(4):420–422. [PubMed]
  • Hume M, Donaldson WR, Suprenant J. Sex, aspirin, and venous thrombosis. Orthop Clin North Am. 1978 Jul;9(3):761–767. [PubMed]
  • Johansson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis. 1981;10(2):89–96. [PubMed]
  • Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily. J Bone Joint Surg Am. 1985 Jan;67(1):57–62. [PubMed]
  • Green D, Rossi EC, Yao JS, Flinn WR, Spies SM. Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. Paraplegia. 1982 Aug;20(4):227–234. [PubMed]
  • Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet. 1980 Dec 20;2(8208-8209):1328–1329. [PubMed]
  • Scurr JH, Coleridge-Smith PD, Hasty JH. Deep venous thrombosis: a continuing problem. BMJ. 1988 Jul 2;297(6640):28–28. [PMC free article] [PubMed]
  • Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg. 1992 Mar;127(3):310–313. [PubMed]
  • Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med. 1987 Apr-May;6(3):245–254. [PubMed]
  • Browse NL, Hall JH. Effect of dipyridamole on the incidence of clinically detectable deep-vein thrombosis. Lancet. 1969 Oct 4;2(7623):718–720. [PubMed]
  • MANTEL N, HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed]
  • Kerrigan GN, Buchanan MR, Cade JF, Regoeczi E, Hirsh J. Investigation of the mechanism of false positive 125I-labelled fibrinogen scans. Br J Haematol. 1974 Mar;26(3):469–473. [PubMed]
  • Lensing AW, Hirsh J. 125I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Thromb Haemost. 1993 Jan 11;69(1):2–7. [PubMed]
  • Saniabadi AR, Tomiak RH, Lowe GD, Barbenel JC, Forbes CD. Dipyridamole inhibits red cell-induced platelet activation. Atherosclerosis. 1989 Apr;76(2-3):149–154. [PubMed]
  • Müller TH, Su CA, Weisenberger H, Brickl R, Nehmiz G, Eisert WG. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol. 1990 Aug;30(2):179–186. [PMC free article] [PubMed]
  • Bergqvist D, Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg. 1985 Feb;72(2):105–108. [PubMed]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Group